The 2026 Compounded GLP-1 Rules: What's Legal, What Isn't, and What to Ask Your Provider

Direct answer: Compounded semaglutide and tirzepatide are not banned in 2026 — but the legal path narrowed sharply once FDA declared both shortages resolved. Mass-produced (“503B”) compounding is off the table; patient-specific (“503A”) compounding is still allowed, but only when a prescriber documents a specific clinical reason — not cost or convenience.

Most patients didn't hear about the biggest GLP-1 policy shift in years from FDA. They heard about it from a price change, a supply email, or a clinic that suddenly stopped replying.

Two dates are behind it. On 2 October 2024, FDA declared the tirzepatide shortage resolved. On 21 February 2025, it did the same for semaglutide.

Nothing about the molecules changed on those days. What changed was who is legally allowed to make copies of them, and under what conditions. That's the whole of the 2026 compounded GLP-1 rules in one paragraph. Here's the version with enough detail to actually protect you — and to help you evaluate whether a provider is following it.

Shortage status is a legal switch, not a supply update

While a drug is officially in shortage, US compounding pharmacies get more room to work. Once FDA calls the shortage over, that room closes. It isn't gradual and it isn't a matter of interpretation.

The part that catches people out: the shortage listing governs the legal category, not what's sitting in a warehouse. Your local pharmacy may still make you wait two weeks for a particular pen. Legally, the shortage is over anyway. Supply friction and shortage status stopped being the same thing in 2025, and a lot of marketing has quietly relied on readers not knowing that.

What the 2026 compounded GLP-1 rules actually changed

Two kinds of compounder exist in US law, and the difference decides what's legitimate now.

503B outsourcing facilities

These make batches. They register with FDA, they're inspected against a drug-manufacturing standard, and they can ship stock to clinics without a patient's name attached to each vial. During the shortage years, a great deal of compounded GLP-1 volume came from this route. With the shortages resolved, they can no longer batch-compound semaglutide or tirzepatide — neither drug appears on the 503B bulk drug substances list.

503A pharmacies

These compound for one named patient at a time, against a specific prescription. That route remains lawful in 2026. It's also narrower than most advertising suggests: a prescriber has to document an individualized clinical reason that this particular patient needs something the commercial product doesn't offer — a dose that isn't commercially available, for example, or a verified allergy to an inactive ingredient in the approved version.

Compliant telehealth platforms - The GLP Doctor is one example - connect patients with licensed doctors who can evaluate their needs and, when appropriate, prescribe compounded medication. Patients can then buy semaglutide online or explore other treatment options, including tirzepatide, through the platform after receiving a prescription from a licensed doctor.

“It's cheaper” isn't one of those reasons. Neither is “the brand is annoying to get hold of.”

503B vs. 503A vs. FDA-approved, at a glance

• 503B outsourcing facilities: made for batch stock with no named patient, reviewed via facility inspection against manufacturing standards. For semaglutide and tirzepatide in 2026: not permitted — the shortages are resolved and neither drug is on the bulks list.
• 503A pharmacies: made for one named patient per prescription, reviewed via state board oversight and pharmacy practice standards. For semaglutide and tirzepatide in 2026: permitted only with a documented individual clinical reason.
• FDA-approved products: made for the general approved population, reviewed via full FDA review of safety, effectiveness, and quality. For semaglutide and tirzepatide in 2026: available and approved.

So when a provider tells you compounded medication is still available, the useful follow-up is: by which route, and what did the prescriber write in my chart?

What FDA actually went after in 2026

In early 2026, FDA sent warning letters to a wave of telehealth companies (see FDA's warning letter database for the current list). The core problem wasn't compounding itself — it was marketing that presented compounded product as equivalent to the FDA-approved brands.

Compounded drugs are not FDA-approved, and they are not reviewed by FDA for safety, effectiveness, or quality. That isn't a footnote technicality. The approved products carry a clinical trial dossier and a manufacturing review behind them; a compounded preparation carries the pharmacy's own standards and your prescriber's judgment. Those can be perfectly reasonable things to rely on — they are simply not the same evidence base. Any company telling you otherwise has just told you something useful about itself.

Five questions worth asking before your next refill

1. Which pharmacy dispenses my medication, by name, and is it licensed in my state?
2. What clinical reason for compounding is documented in my chart?
3. Am I being told this is the same as Wegovy, Ozempic, Mounjaro, or Zepbound? If yes, treat that as a warning sign rather than reassurance.
4. Who is my prescriber, what's their license number, and how do I reach a clinician about a side effect on a Sunday night?
5. What happens to my treatment plan if the compounded route closes for me?

Question five is the one people skip. Ask it anyway — the answer tells you whether you're dealing with a clinic or a storefront.

Checking a license takes about four minutes: every state medical and pharmacy board publishes a free, searchable lookup. If a provider can't or won't give you a pharmacy name and license number, that's your answer.

The trade-off nobody frames honestly

Here's the concession: plenty of patients did well on compounded GLP-1s during the shortage years, and telling them their experience was imaginary would be both rude and wrong.

At the same time, “it worked for me” doesn't answer a regulatory question, and 2026 is a regulatory question. The honest position sits in the middle: compounding has a legitimate, narrow place in American pharmacy, for the patient the mass-produced product genuinely doesn't fit. It isn't a general-purpose discount channel. The providers worth trusting document that individualized reason for every compounded prescription they write, precisely so patients aren't left holding a prescription that can't be defended if the rules tighten further.

If you're mid-treatment right now

Don't stop anything because of a policy article — that decision belongs with the person who prescribed it, and stopping a weight-management medication has its own consequences worth planning for.

Do get answers to those five questions in writing. Do check your provider's license. And do ask, plainly, what your options look like if you'd rather move to an FDA-approved product — there are more of those available in 2026 than there were two years ago.

If you're already on a compounded product and want a second opinion on whether your prescription would hold up under the current rules, that's a conversation worth having with your prescriber directly - or with a new one, if you're not confident in the answers you're getting.

One last thing about brand names

Ozempic, Wegovy, Mounjaro, and Zepbound are trademarks of their respective owners, and each name refers to a specific FDA-approved product. When a compounding-based service borrows those names to describe what it sells you, the name is doing work it isn't entitled to do. Watch for it — in a confusing market, it's the clearest single tell there is.

Frequently Asked Questions

Is compounded semaglutide illegal now?

No, but the lawful route is narrower. Batch compounding by outsourcing facilities is off the table; patient-specific compounding by a 503A pharmacy is still permitted where a prescriber documents an individual clinical reason.

Does a documented clinical reason include cost?

No. Cost is not a clinical reason. Examples that can qualify include a dose that isn't commercially available or a verified allergy to an inactive ingredient in the approved product.

What's the actual difference between a 503A and 503B pharmacy?

A 503B outsourcing facility makes batches of medication in advance, without a specific patient attached, and is inspected against manufacturing standards. A 503A pharmacy compounds one prescription at a time for one named patient, under state board oversight. Only 503A compounding of semaglutide and tirzepatide remains legal in 2026.

Is compounded medication tested like the brand-name drugs?

No. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. That doesn't make them illegitimate - it means the evidence base is different, and it's worth knowing which one you're relying on.

How do I verify my prescriber or pharmacy is properly licensed?

Every state medical board and pharmacy board publishes a free public lookup tool. Search by the provider's or pharmacy's name and license number - it takes about four minutes and confirms both that the license is active and that it's in good standing.

Can I switch from a compounded GLP-1 to an FDA-approved one?

Often, yes — it depends on your clinical history and what's working for you. A licensed physician can review your treatment history and walk you through what an FDA-approved product would look like for your plan, including dosing and cost differences.